Brief: Zealand Pharma Says Phase 3 Zupreme Trials Expected To Enroll About 7,000 Participants
22/09/2026 16:25
BRIEF-Zealand Pharma Says Phase 3 Zupreme Trials Expected To Enroll About 7,000 Participants Sept 22 (Reuters) - Zealand Pharma A/S ZELA.CO:
ZEALAND PHARMA ANNOUNCES INITIATION OF THE REGISTRATIONAL PHASE 3 ZUPREME PROGRAM OF PETRELINTIDE IN PEOPLE WITH OVERWEIGHT OR OBESITY
ZEALAND PHARMA - PHASE 3 ZUPREME TRIALS EXPECTED TO ENROLL ABOUT 7,000 PARTICIPANTS
Source text: ID:nGNX12xsdz
Further company coverage: ZELA.CO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)